comparemela.com

Page 2 - எலும்பு தசை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Affinia Therapeutics Presents New Data and Updates on AAV Platform at American Society of Gene and Cell Therapy Annual Meeting

Share: WALTHAM, Mass., May 13, 2021 (GLOBE NEWSWIRE) Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies for rare and non-rare diseases, today announced results from preclinical studies presented in poster and oral sessions at the American Society of Gene and Cell Therapy (ASGCT) 24 Challenges in achieving adequate expression in the central nervous system (CNS) with conventional AAV vectors have limited the use of gene therapy to address many devastating rare and non-rare CNS diseases. Affinia Therapeutics presented data in a poster session on its proprietary AAV vector Anc80L65 showing superiority to AAV9 in various non-human primate (NHP) CNS regions after a single intrathecal injection. When delivered via lumbar puncture, Anc80L65 demonstrated up to 32-fold higher RNA expression versus AAV9 delivered via the more invasive intracisternal route of administration. An

Low glucose levels might assist muscle repair, finds study

Avidity Biosciences Reports Fourth Quarter and Year-End 2020 Financial Results and Recent Highlights

Share this article Share this article LA JOLLA, Calif., March 15, 2021 /PRNewswire/ Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the fourth quarter and year ended December 31, 2020 and highlighted recent corporate progress.        In 2020, we made significant advances across our AOC pipeline and platform. Our work supports Avidity s evolution to a clinical-stage company as we plan to advance AOC 1001 into the clinic in the second half of this year and progress our FSHD and DMD programs, said Sarah Boyce, President and Chief Executive Officer.  Our discovery efforts continue to focus on expanding our AOC platform into additional muscle diseases and other tissues as we begin to realize our vision of profoundly improving people s lives by revolutionizing the delivery of RNA treatments.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.